Phase 1 Trial: Simple Dietary Supplement Could Supercharge Cancer-Fighting Immune Cells
/0 Comments/in Clinical Trial, Not PCa related/by MaxNewsletter 7
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week HAPPY NEW YEAR! Before we dive into the latest news from prostatewarriors.com I want to wish you all a great 2025! The seventh and final newsletter of 2024 is here, bringing you fresh insights and renewed hope. We also have a podcast if you prefer […]
Phase 1 Trial Recruiting: Bispecific Antibodies JNJ-87189401 and JNJ-78278343
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxTargeting LIG1 with PARP Inhibitors: E New Target Identified Using CRISPR
/0 Comments/in CRISPR, PARPi, Preclinical Research/by MaxNew Nanoparticle Therapy Holds Promise for Prostate Cancer Patients
/0 Comments/in Delivery, Preclinical Research/by MaxRepurposing FDA-Approved Drugs for PIM-1 Kinase Inhibition: A Potential Avenue for Prostate Cancer
/0 Comments/in Drug repurposing, Preclinical Research/by MaxXaluritamig (AMG 509): Promising Updates on a STEAP1-Targeted Therapy for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 trial: AVA6000 Targeted Chemotherapy for FAP-Positive Tumors (Including Prostate Cancer)
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025
- Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025
- UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC June 5, 2025